SCHEMBL30837875

SCHEMBL30837875

N#Cc1cc(Cn2c(=O)c3cc(OC(CF)CF)c(F)cc3n(C3CCN(C=O)CC3)c2=O)ccc1-c1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PDE7A Q13946 10/20 0.81
▸ PDE7B Q9NP56 5/20 0.81
▸ PDE8A O60658 3/20 0.81
▸ NPSR1 Q6W5P4 3/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ C5AR1 P21730 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ TSHR P16473 1/20 0.33
▸ CRHBP P24387 1/20 0.33
▸ CRHR2 Q13324 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ AKT1 P31749 3/20 0.33
▸ AKT2 P31751 3/20 0.33
▸ CYP19A1 P11511 1/20 0.33
▸ CYP3A4 P08684 1/20 0.32
▸ DPP4 P27487 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL100403 1.00 PDE7A (0.81) PDE7APDE7BPDE8ANPSR1ALDH1A1
SCHEMBL101130 0.89 PDE7A (1.00) PDE7APDE7BPDE8ANPSR1ALDH1A1
SCHEMBL32681327 0.89 PDE7A (1.00) PDE7APDE7BPDE8ANPSR1ALDH1A1
SCHEMBL100173 0.89 PDE7A (0.67) PDE7APDE7BPDE8ANPSR1ALDH1A1
SCHEMBL101013 0.86 PDE7A (0.62) PDE7APDE7BPDE8ANPSR1ALDH1A1
SCHEMBL101016 0.85 PDE7A (0.61) PDE7APDE7BPDE8ANPSR1ALDH1A1
SCHEMBL100389 0.84 PDE7A (0.58) PDE7APDE7BPDE8ANPSR1TSHR
SCHEMBL30837787 0.84 PDE7A (0.58) PDE7APDE7BPDE8ANPSR1TSHR
SCHEMBL595052 0.83 PDE7A (0.60) PDE7APDE7BPDE8ANPSR1ALDH1A1
SCHEMBL100501 0.83 PDE7A (0.62) PDE7APDE7BPDE8ANPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260060970-A1 Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance MITODICURE GMBH (DE) 2026-03-05 — — US disclosed
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 — — EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060970-A1 Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance PDE5A, PDE4C, PDE12 PDE7A 5/4885PDE7B 14/4885PDE8A 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback